检测中国结直肠癌患者粪便样本中的甲基化组织因子途径抑制物 2 和人长 DNA。
Detection of methylated tissue factor pathway inhibitor 2 and human long DNA in fecal samples of patients with colorectal cancer in China.
机构信息
Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
出版信息
Cancer Epidemiol. 2012 Feb;36(1):73-7. doi: 10.1016/j.canep.2011.04.006. Epub 2011 May 28.
BACKGROUND
To investigate the feasibility of detecting methylated tissue factor pathway inhibitor (TFPI2) and quantifying human long DNA with fluorescent quantitative Alu PCR in fecal DNA as a non-invasive screening tool for colorectal cancer (CRC).
MATERIALS AND METHODS
Methylation-specific PCR (MSP) was performed to analyze TFPI2 gene promoter methylation status in a blinded fashion in stool samples taken from 30 endoscopically diagnosed healthy controls, 20 patients with adenomas, and 60 patients with colorectal cancer. Real-time Alu PCR was used to quantify human long DNA.
RESULTS
The specificity of fecal TFPI2 MSP assay and long DNA assay was 100% and 83.3%, respectively. The sensitivity of fecal TFPI2 MSP assay and long DNA assay was 68.3% and 53.3%, respectively. The sensitivity of fecal DNA assay (either marker being positive) was 86.7%, which was high for CRC.
CONCLUSIONS
Our results have demonstrated the feasibility of using TFPI2 methylation and quantify human long DNA with fluorescent quantitative Alu PCR in fecal samples as a new noninvasive test for CRC.
背景
为了研究在粪便 DNA 中检测组织因子途径抑制物（TFPI2）甲基化和定量人长 DNA 的荧光定量 Alu PCR 作为结直肠癌（CRC）非侵入性筛查工具的可行性。
材料和方法
采用甲基化特异性 PCR（MSP）对 30 例内镜诊断的健康对照者、20 例腺瘤患者和 60 例结直肠癌患者的粪便样本进行 TFPI2 基因启动子甲基化状态的盲法分析。采用实时 Alu PCR 定量人长 DNA。
结果
粪便 TFPI2 MSP 检测和长 DNA 检测的特异性均为 100%，敏感性分别为 68.3%和 53.3%。粪便 DNA 检测（任一标志物阳性）的敏感性为 86.7%，对 CRC 较高。
结论
我们的结果表明，在粪便样本中使用 TFPI2 甲基化和定量人长 DNA 的荧光定量 Alu PCR 作为 CRC 的新型非侵入性检测方法是可行的。
Zotero 插件